


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">31198183</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1524-4733</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>22</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</Title>
                <ISOAbbreviation>Value Health</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>661-668</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S1098-3015(19)30186-X</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jval.2019.03.012</ELocationID>
            <Abstract>
                <AbstractText>The concept of a reference case, first proposed by the US Panel on Cost-Effectiveness in Health and Medicine, has been used to specify the required methodological features of economic evaluations of healthcare interventions. In the case of gene therapy, there is a difference of opinion on whether a specific methodological reference case is required. The aim of this article was to provide a more detailed analysis of the characteristics of gene therapy and the extent to which these characteristics warrant modifications to the methods suggested in general reference cases for economic evaluation. We argue that a completely new reference case is not required, but propose a tailored checklist that can be used by analysts and decision makers to determine which aspects of economic evaluation should be considered further, given the unique nature of gene therapy.</AbstractText>
                <CopyrightInformation>Copyright © 2019 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Drummond</LastName>
                    <ForeName>Michael F</ForeName>
                    <Initials>MF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centre for Health Economics, University of York, York, England, UK. Electronic address: mike.drummond@york.ac.uk.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Neumann</LastName>
                    <ForeName>Peter J</ForeName>
                    <Initials>PJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sullivan</LastName>
                    <ForeName>Sean D</ForeName>
                    <Initials>SD</Initials>
                    <AffiliationInfo>
                        <Affiliation>CHOICE Institute, School of Pharmacy, University of Washington, Seattle, WA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fricke</LastName>
                    <ForeName>Frank-Ulrich</ForeName>
                    <Initials>FU</Initials>
                    <AffiliationInfo>
                        <Affiliation>Fakultät Betriebswirtschaft, Technische Hochschule Nürnberg Georg Simon Ohm, Nürnberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tunis</LastName>
                    <ForeName>Sean</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Medical Technology Policy, Baltimore, MD, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dabbous</LastName>
                    <ForeName>Omar</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>AveXis Inc, Bannockburn, IL, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Toumi</LastName>
                    <ForeName>Mondher</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Public Health Department, Aix-Marseille University, Marseille, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Value Health</MedlineTA>
            <NlmUniqueID>100883818</NlmUniqueID>
            <ISSNLinking>1098-3015</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">cost-effectiveness analysis</Keyword>
            <Keyword MajorTopicYN="N">drug pricing</Keyword>
            <Keyword MajorTopicYN="N">reimbursement</Keyword>
            <Keyword MajorTopicYN="N">specialty drugs</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>01</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31198183</ArticleId>
            <ArticleId IdType="pii">S1098-3015(19)30186-X</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jval.2019.03.012</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

